FDA OKs Novartis’ canakinumab for rare type of arthritis

The FDA approves Novartis’ (NVS +1.6%) Ilaris (canakinumab) for the treatment of adult-onset Still’s disease, a rare type of inflammatory arthritis characterized by fever, rash and joint pain.

The FDA originally approved the interleukin-1-beta blocker in June 2009 for a rare inflammatory disorder called cryopyrin-associated periodic syndrome (CAPS). Indications for juvenile idiopathic arthritis and three rare periodic fever syndrome were added in May 2013 and September 2016, respectively.

https://seekingalpha.com/news/3583557-fda-oks-novartis-canakinumab-for-rare-type-of-arthritis